Takeda’s (TAK +0.2%) Shire plc is the winner of a challenge to two patents protecting long-acting ADHD med Mydayis by a would-be generic competitor. The USPTO’s Patent Trial and Appeal Board ruled that KVK-Tech failed to prove that the patents, covering the method of releasing the drug, are invalid.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.